



RECEIVED

AUG 08 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jordan J. N. Tang, Xinli Lin, Gerald Koelsch, and Lin Hong

Serial No: 09/604,608

Art Unit: 1625

Filed: February 18, 2000

Examiner: D. Seaman

For: *CATALYTICALLY ACTIVE RECOMBINANT MEMAPSIN AND
METHODS OF USE THEREOF*

Assistant Commissioner
for Patents
Washington, D. C. 20231

**POWER OF ATTORNEY BY ASSIGNEE OF THE ENTIRE INTEREST
AND REVOCATION OF PRIOR POWERS**

Sir:

As owner of the entire interest of the above-identified patent application, all powers of attorney previously given are hereby revoked and the following attorneys and agents are hereby appointed to prosecute and transact all business in the Patent and Trademark Office connected therewith:

Patrea L. Pabsi
Zhaoyang Li
Rivke Morheit

Registration No. 31,284
Registration No. 46,872
Registration No. P-48,731

Please send all correspondence relating to the above-identified patent application to:

Patrea L. Pabsi
HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, Suite 2000
Atlanta, Georgia 30309-3400

(404) 817-8473 - Telephone
(404) 817-8588 - Telefax

JUL 26 2001 11:22

#4930 P.002/004

RECEIVED

AUG 08 2001

TECH CENTER 1600/2900



U.S. N. C. 004,008
Filed June 27, 2000
Power of Attorney by Assignee of Entire
Interest and Revocation of Prior Powers

The undersigned signatory (whose title is supplied below) is empowered to act on behalf of the assignee identified below, and has reviewed all the documents in the chain of title of the patent application and, to the best of undersigned's knowledge and belief, title is in the assignee.

OKLAHOMA MEDICAL RESEARCH FOUNDATION

By:

Name:

Title:

Larry J. Kennedy
Larry J. Kennedy
Director, Technology Transfer

Date:

July 26, 2001

ATTL #472078 v1

AUG 08 2001



~~Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.~~

TECH CENTER

Application No./Patent No.: 03/306,988

Filed/Issue Date: February 18, 2009

Entitled: PROTEASE INHIBITORS THAT OVERCOME DRUG RESISTANCE

Oklahoma Medical Research Foundation, a University

(Name of Applicant)

Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

1. ☒ the assignee of the entire right, title, and interest; or

2. ☒ an assignee of an undivided part interest

In the patent application/patent identified above by virtue of either:

A. [x] An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office's Serial 010772, Frame 5819, or for which a copy thereof is attached.

OR

B. () A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____ or for which a copy thereof is attached

2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____ Frame _____ or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel: _____ Frame _____ or for when a copy thereof is attached.

() Additional documents in the chain of title are listed on a supplemental sheet.

1. Copies of assignments or other documents in the chain of title are attached.
NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

July 26, 2001
Date

_____ Signature

Harry J. Kennedy
Typed or printed name

Director, Technology Transfer